Starpharma Holdings Limited (ASX: SPL) has announced the completion of the phase 1 component of its phase 1 / 2 trial for DEP® cabazitaxel. The trial was able to meet its objective of assessing safety, tolerability and preliminary efficacy data, and identifying a recommended phase 2 dose of 20 mg/m2.
In phase 1, the trial was conducted on 14 patients diagnosed with several forms of cancer. Efficacy signals were noticed in 67% of evaluable patients. It comprised of prolonged stable disease and significant reduction in specific tumour biomarkers like prostate specific antigen. Efficacy signals was also observed in various types of tumour like prostate, ovarian, cholangiocarcinoma and pancreatic cancer.
DEP® cabazitaxel patients had less side effects (vomiting and bone marrow toxicity) than those patients with conventional cabazitaxel.
Phase 2 will initiate immediately.
There is no investor left unperturbed with the ongoing trade conflicts between US-China and the devastating bushfire in Australia.
Are you wondering if the year 2020 might not have taken the right start? Dividend stocks could be the answer to that question.
As interest rates in Australia are already at record low levels, find out which dividend stocks are viewed as the most attractive investment opportunity in the current scenario in our report.